CAncer Survivor CArdiomyopathy DEtection (CASCADE) Pilot Study

Overview

About this study

The purpose of this study is to improve the cardiovascular care of adult cancer survivors by contributing much-needed evidence regarding optimal surveillance and treatment recommendations. This application’s objective is to obtain the data necessary to plan an adequately powered randomized clinical trial (RCT) across a nation-wide network that will define prospectively the clinical and economic efficacy of a screening program that uses AI-ECG and/or NT-pro-BNP in an at-risk adult cancer survivor population.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

- ≥ 18 years of age at the time of enrollment

- diagnosis of breast cancer, lymphoma, or sarcoma with either planned or at 1 year
after completion of anthracycline therapy, including patients from 6-12 months and
greater than 1 year post-anthracycline exposure.

Exclusion Criteria:

- LVEF < 50% or prior confirmed history of cardiomyopathy, heart failure, persistent
atrial fibrillation, left bundle branch block, or paced rhythm

- Individuals with pacemakers, defibrillators, or other implanted electronic devices

- Diagnosed with stage 4

- Diagnosed with metastatic disease not being treated with curative intent

- Prior or planned HER2-directed chemotherapy

- Inability/unwillingness of individual to give written informed consent

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 3/21/2024. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Joerg Herrmann, M.D.	Open for enrollment	Contact information: Tiffany Hansen (507) 293-0196 Hansen.Tiffany@mayo.edu

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Joerg Herrmann, M.D.

Open for enrollment

Contact information:

Tiffany Hansen

(507) 293-0196

Hansen.Tiffany@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials